Ajou University repository

OncoImmunology
ISSN
  • E2162-402X
  • P2162-4011
Publisher

Landes Bioscience

Listed on
(Coverage)

JCR2013-2023

SJR2013-2020;2022-2023

CiteScore2012-2023

SCIE2013-2024

SCOPUS2017-2024

MEDLINE2021-2024

DOAJ2020-2024

EMBASE2016-2024

OA Info.
OA oa mark

based on the information

  • 2020;2021;2022;2023;2024;2025;
Keywords oncology, immunology, immunotherapy, tumour immunology
Review Process Anonymous peer review
Journal info.
pages
Licences CC BY, CC BY-NC
Copyrights No
DOAJ Coverage Added on Date : 2020-05-11T11:24:01Z
Subject(s) Medicine: Internal medicine: Specialties of internal medicine: Immunologic diseases. Allergy | Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Active
Active

based on the information

  • SCOPUS:2024-10
Country
USA
Aime & Scopes
Tumor immunology deals with the natural or therapy-induced recognition of cancers, as well as with the intricate interplay between oncogenesis, inflammation and immunosurveillance. This high-profile journal, OncoImmunology specifically deals with tumor immunology. Recent progress has allowed for the first clinical demonstration (and FDA approval) of anticancer immunotherapies. There is also an ever growing suspicion that - unexpectedly - many of the currently used chemotherapeutic agents depend in their efficacy on the active contribution of immune effectors. To use a drastic metaphor, oncologists who applied successful chemotherapeutic (or radiotherapeutic) regimens have taken advantage of the immune system's capacity to recognize tumor-specific or tumor-associated antigens and to control cancer (stem) cell growth, without being aware of the invisible helping hands. As a result, immunological biomarkers are becoming ever more important to determine the prognosis of cancers and to predict the efficacy of chemotherapies. There is also a strong rationale in favor of combining conventional anticancer therapies with immunotherapies. OncoImmunology accepts high-profile submissions in the fundamental, translational and clinical areas of tumor immunology. Submissions dealing with solid or hematological cancers, inflammation, innate and acquired immune responses are welcome.
Article List

Showing results 1 to 1 of 1

Heterodimeric Fc-fused IL12 shows potent antitumor activity by generating memory CD8+ T cellsoa mark
  • Jung, Keunok;
  • Ha, Ji Hee;
  • Kim, Jung Eun;
  • Kim, Jeong Ah;
  • Kim, Ye Jin;
  • Kim, Chul Ho;
  • Kim, Yong Sung
  • 2018-07-03
  • OncoImmunology, Vol.7 No.7
  • Taylor and Francis Inc.
1